Search clinical trials for: CCAR

Total 1247 results

Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Nanjing Legend Biotech Co.
Janssen Research & Development, LLC

Recruiting

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)

Multiple Myeloma

China
Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west...

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

China
Janssen Research & Development, LLC

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Multiple Myeloma

United States, Belgium, China, Israel, Netherlands, Spain, Japan
Nanjing Legend Biotech Co.
Ruijin Hospital; Second Affiliated Hospital of Xi'an Jiaotong University; Shanghai... and other collaborators

Active, not recruiting

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)

Refractory or Relapsed Multiple Myeloma
BioSyngen Pte Ltd

Completed

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

EBV-positive Nasopharyngeal Carcinoma

China
United States Army Research Institute of Environmental...

Not yet recruiting

Effect of Ration Formulations on Warfighter Energy Balance and Physical Performance During a Field Training Exercise

Healthy Volunteers

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
iCell Gene Therapeutics
iCAR Bio Therapeutics Ltd. China

Recruiting

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Plasmacytoid; Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
iCell Gene Therapeutics
The General Hospital of Western Theater Command; Peking University Shenzhen... and other collaborators

Recruiting

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
University of Calgary
Alberta Health services; Alberta Innovates Health Solutions

Recruiting

Optimizing Postpartum Pelvic Health Through Self-Scar Tissue Massage of Episiotomy and Perineal Scar Tissue A Pilot RCT (EPIS)

Scar Tissue | Perineal Tear | Episiotomy; Complications | Vaginal Tear Resulting From Childbirth

Canada
Lili Cao

Recruiting

Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions

Scar | Intrauterine Adhesion

China
Synochi, LLC
LAC+USC Medical Center

Not yet recruiting

Prospective Placebo-controlled Study of Synochi Scar Spray

Burns Multiple
University Hospital, Ghent

Completed

Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels and One Gel Cream

Scar Tissue or Healthy Skin

Belgium
Chunrui Li
Nanjing IASO Biotechnology Co., Ltd

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Assiut University

Not yet recruiting

Removal Versus Non Removal of Ceserean Section Scar . (cs)

Cesarean Wound; Dehiscence
Jessa Hospital

Completed

Evaluation of the Cosmetic Outcomes of Totally Endoscopic Cardiac Surgery (SCARMICS)

Scar | Minimally Invasive Cardiac Surgery

Belgium
University of British Columbia

Completed

Does Scar Massage Improve Postoperative Pain and Function in Women With Breast Cancer?

Breast Cancer

Canada
Rennes University Hospital

Recruiting

Effect of Intense Sport Practice in Athletes With Non-ischemic Scar (EISCAR)

Athletes With Isolated Non-ischemic LGE With no Underlying "Labelled" Cardiomyopathy

France, Australia, Belgium, Germany, Luxembourg, United Kingdom
Shanghai East Hospital
Nanjing Legend Biotech Co.

Terminated

A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors

Solid Tumors, Adult

China
US Department of Veterans Affairs

Completed

Cognitive Remediation for Schizophrenia

Schizophrenia

United States
Cellular Biomedicine Group Ltd.
Chinese PLA General Hospital

Unknown

A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
Cellular Biomedicine Group Ltd.
The First Affiliated Hospital with Nanjing Medical University

Completed

A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects (C-CAR011)

Refractory Diffuse Large B-Cell Lymphoma

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
Region Skane

Completed

Effect of Surgical Site Infections on Patient Reported Cosmetic Outcomes in Dermatologic Surgery

Surgical Site Infection | Patient Satisfaction

Sweden
Sultan Qaboos University

Completed

VAGABOND: a Mnemonic to Aid in the Memory Retention of the Canadian CT Head Rule

Traumatic Brain Injury | Education

Oman
jianming xu
Nanjing Legend Biotech Co.

Recruiting

GPC3-targeting LCAR-H93T Cell in Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

B-cell Non Hodgkin Lymphoma

China
Nexcella Inc.

Not yet recruiting

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis (NEXICART-2)

Light Chain (AL) Amyloidosis

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

Relapsed and Refractory B-cell Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

B-cell Non Hodgkin Lymphoma

China
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Zagazig University

Recruiting

Laparoscopic Versus Combined Laparoscopic and Hysteroscopic Repair of CS Niche

Cesarean Scar Niche

Egypt
University Hospital, Ghent
Belgian Foundation for Burn Injuries, Belgium

Completed

Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Site After Wound Closure

Wounds

Belgium
Weijun Fu
Nanjing Legend Biotech Co.

Recruiting

BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Necmettin Erbakan University

Completed

Bladder Suture in Uterus-Sparing Surgery and Hysterectomy for Placenta Percreta

Bladder Injury | Sutures | Placenta Percreta

Turkey
Weijun Fu
Nanjing Legend Biotech Co.

Active, not recruiting

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Withdrawn

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

United States
Nanjing IASO Biotechnology Co., Ltd.
Ruijin Hospital

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma | Acute Lymphoblastic Leukemia

China
Berufsgenossenschaftliche Unfallklinik Ludwigshafen
Central Institute of Mental Health, Mannheim

Recruiting

Scar Resection and Reconstruction With Integra and Split Skin Grafts in Patients With Non-Suicidal Self-Inflicted Scars

Cicatrix | Nonsuicidal Self Injury | Stigmatization | Skin Transplantations

Germany
Institute of Hematology & Blood Diseases Hospital...
Nanjing Legend Biotech Co.

Terminated

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
920th Hospital of Joint Logistics Support Force...
Nanjing Bioheng Biotech Co., Ltd.

Withdrawn

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

B-cell Lymphoma

China

Search clinical trials for: CCAR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations